The study population was 600,000 veterans, tracked over up to four years. The finding was this: people taking GLP-1 receptor agonists — the drug class that includes Ozempic, Wegovy, and Mounjaro — had significantly lower rates of every measured substance use disorder. Alcohol. Opioids. Tobacco. Cannabis. [1] The study, published in the BMJ and conducted by researchers at Washington University in St. Louis, is the largest epidemiological analysis of GLP-1 drugs and addiction to date.

The magnitude of the effect was not small. Patients on GLP-1 drugs had an 18 percent lower risk of developing alcohol use disorder compared to matched controls not taking the drugs. Opioid use disorder risk dropped by 25 percent. Tobacco use disorder risk fell by approximately 20 percent. [2] The reductions held across age, race, sex, and whether the patient had a prior history of addiction. The drug did not merely help addicts recover. It prevented addiction from developing in the first place.

The mechanism is not fully understood, but the hypothesis is increasingly precise. GLP-1 receptors are found not only in the gut and pancreas — where they regulate appetite and blood sugar — but in the brain's mesolimbic dopamine pathway, the neural circuit that governs reward, pleasure, and craving. [3] The drugs appear to modulate the same system that addiction hijacks. They reduce the experience of reward from substances without producing euphoria of their own. They are, in pharmacological terms, a dimmer switch on wanting.

This finding arrives in a GLP-1 landscape that is already overwhelming. The Wegovy pill — an oral formulation of semaglutide approved by the FDA in December 2025 and launched in January 2026 — has reportedly reached over 400,000 subscribers in its first three months. [4] At $149 per month at the lowest dose, it represents a massive new revenue stream for Novo Nordisk and a massive new expense for the health system. The oral version achieved 16.6% mean weight loss at 64 weeks in clinical trials, comparable to the injectable formulation. [4]

Simultaneously, the FDA is cracking down on the compounding pharmacies and telehealth platforms that have been selling unapproved GLP-1 formulations. In March, the agency issued warning letters to 30 telehealth companies for illegal marketing of compounded semaglutide and tirzepatide. [5] The enforcement action follows over 55 warning letters issued in September 2025. The compounded market, which emerged during GLP-1 shortages and offered the drugs at a fraction of branded prices, is being systematically dismantled.

The three stories form a single narrative: GLP-1 drugs are expanding into addiction treatment, expanding into oral delivery, and contracting in the compounded market that made them accessible to millions who could not afford the branded versions. The drugs keep getting better. Access keeps getting more complicated.

The addiction findings are the most medically significant development. The opioid epidemic killed approximately 80,000 Americans in 2025. If a drug that is already prescribed to millions for weight loss also reduces opioid addiction risk by a quarter, the public health implications are staggering. [6] The question is whether the healthcare system — insurance companies, formularies, prior authorization regimes — will recognize addiction prevention as a valid indication, or whether GLP-1 drugs will remain categorized as weight loss medications with addiction reduction as an accidental side benefit.

NBC News framed the question bluntly: "Is addiction next?" [7] The answer, based on the largest study anyone has conducted, appears to be yes. The question is not whether GLP-1 drugs reduce addiction risk. The question is what we do with that knowledge.

-- NORA WHITFIELD, Boston